Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Corporate Insiders at Alcoa Inc. (AA) and Two Other Battered Companies Keep Buying Shares

Biopharmaceutical Company Witnesses Cluster of Insider Buying

CymaBay Therapeutics Inc. (NASDAQ:CBAY) has registered a cluster of insider buying in April involving three different executives. Patrick J. O’Mara, Vice President for Business Development, bought 5,000 shares on Friday at a cost of $1.64 per share, lifting his holding to 5,022 shares. Charles A. McWherther, Senior Vice President and Chief Scientific Officer, acquired 3,000 units of common stock on Friday at a price tag of $1.68 per share. After the recent purchase, Dr. McWherther owns 5,000 shares. Last but not least, Chief Financial Officer Sujal Shah purchased 55,000 shares at the beginning of April for $1.39 each.

The clinical-stage biopharmaceutical company focused on developing therapies for the treatment of metabolic diseases has seen its shares advance an impressive 33% since the beginning of 2016. However, the stock is down 55% in the past 52 weeks. CymaBay Therapeutics focuses on two key clinical assets: MBX-8025, which is designed for the treatment of various orphan and liver diseases; and arhalofenate, developed for the treatment of gout. CymaBay has successfully completed end-of-Phase 2 meeting discussions with the FDA regarding arhalofenate, but the company is currently discussing with possible partners to combine forces for the initiation of Phase 3 development for the drug this year.

The number of money managers from our database with positions in the clinical-stage biopharmaceutical company declined to seven from ten during the December quarter, with those ten funds accumulating almost 21% of the company’s outstanding shares. Adage Capital Management, founded by Phil Gross and Robert Atchinson, was the largest equity holder of CymaBay Therapeutics Inc. (NASDAQ:CBAY) on December 31 with 1.70 million shares.

Follow Cymabay Therapeutics Inc. (NASDAQ:CBAY)
Trade (NASDAQ:CBAY) Now!

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.